Perichondrium Autograft in Refractory Necrotizing Scleritis (PCRNS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02864823|
Recruitment Status : Completed
First Posted : August 12, 2016
Last Update Posted : August 12, 2016
Necrotizing scleritis with severe ischemia is refractory to conventional treatment because of avascular necrosis.
The investigators assessed the therapeutic efficacy and safety of autologous perichondrium transplantation in patients with severe ischemic necrotizing scleritis, and analyzed the therapeutic effects.
|Condition or disease||Intervention/treatment||Phase|
|Necrotizing Scleritis||Procedure: Perichondrium Autografts||Not Applicable|
Ischemic necrotizing scleritis patients who showed persistent and progressive scleral melting were included in this study.
Perichondrium tissue was harvested from the patient's ear cartilage and transplanted to reconstruct the scleral defect after the necrotic tissue removal.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Autologous Perichondrium Transplantation for Replacement of Stem Cells and Their Niche in the Treatment of Necrotizing Scleritis|
|Study Start Date :||March 2011|
|Actual Primary Completion Date :||June 2016|
|Actual Study Completion Date :||June 2016|
Procedure: Perichondrium Autografts
Perichondrium tissue was harvested from the patient's ear cartilage and transplanted to reconstruct the scleral defect.
Other Name: Perichondrium Transplantation
- Success Rate of Repair of Scleral Defects [ Time Frame: Six months after reconstructive surgery ]Success Rate of Repair of Scleral Defects
- Post-Operative Complications [ Time Frame: Six months after reconstructive surgery ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02864823
|Korea, Republic of|
|Chung Ang University Hospital|
|Seoul, Korea, Republic of, 156-755|
|Principal Investigator:||Jae Chan Kim, Ph.D.||Chung-Ang University Hosptial, Chung-Ang University College of Medicine|
|Study Director:||Jee Taek Kim, Ph.D.||Chung-Ang University Hosptial, Chung-Ang University College of Medicine|